Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 10 (October)

1. Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma.
   Am J Ophthalmol, 142(4): 693-5. [Abstract] [Full-text]
2. Alcohol consumption and ovarian cancer risk in a population-based case-control study.
   Int J Cancer, 119(10): 2423-7. [Abstract] [Full-text]
3. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
   Int J Cancer, 119(10): 2304-12. [Abstract] [Full-text]
4. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
   J Natl Cancer Inst, 98(19): 1397-405. [Abstract] [Full-text]
5. Molecular and pathologic aspects of endometrial carcinogenesis.
   J Clin Oncol, 24(29): 4783-91. [Abstract] [Full-text]
6. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
   BMC Cancer, 6: 228. [Abstract] [Full-text]
7. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
   J Clin Oncol, 24(29): 4699-707. [Abstract] [Full-text]
8. Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas.
   Cancer Lett, 243(1): 120-7. [Abstract] [Full-text]
9. Association of decreased mitochondrial DNA content with ovarian cancer progression.
   Br J Cancer, 95(8): 1087-91. [Abstract] [Full-text]
10. Gene expression profiling of human ovarian tumours.
    Br J Cancer, 95(8): 1092-100. [Abstract] [Full-text]
11. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.
    J Clin Oncol, 24(30): 4862-6. [Abstract] [Full-text]
12. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus.
    Am J Clin Pathol, 126(5): 709-16. [Abstract] [Full-text]
13. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III.
    Mol Carcinog, 45(11): 851-60. [Abstract] [Full-text]
14. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
    Clin Cancer Res, 12(20): 6170-8. [Abstract] [Full-text]
15. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
    Clin Cancer Res, 12(20): 6106-15. [Abstract] [Full-text]
16. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
    Clin Cancer Res, 12(20): 5944-50. [Abstract] [Full-text]
17. Ovarian cancer: patterns of surgical care across the United States.
    Gynecol Oncol, 103(2): 383-90. [Abstract] [Full-text]
18. Hypercalcemia induced by ovarian clear cell carcinoma producing all transcriptional variants of parathyroid hormone-related peptide gene during pregnancy.
    Gynecol Oncol, 103(2): 740-4. [Abstract] [Full-text]
19. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
    Gynecol Oncol, 103(2): 755-8. [Abstract] [Full-text]
20. Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.
    Gynecol Oncol, 103(2): 752-4. [Abstract] [Full-text]
21. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Gynecol Oncol, 103(2): 703-8. [Abstract] [Full-text]
22. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail.
    Gynecol Oncol, 103(2): 623-30. [Abstract] [Full-text]
23. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
    Gynecol Oncol, 103(2): 575-80. [Abstract] [Full-text]
24. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer.
    Gynecol Oncol, 103(2): 667-72. [Abstract] [Full-text]
25. Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer.
    Gynecol Oncol, 103(2): 673-8. [Abstract] [Full-text]
26. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
    Gynecol Oncol, 103(2): 591-8. [Abstract] [Full-text]
27. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
    Gynecol Oncol, 103(2): 608-13. [Abstract] [Full-text]
28. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
    Gynecol Oncol, 103(2): 692-7. [Abstract] [Full-text]
29. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Gynecol Oncol, 103(2): 637-41. [Abstract] [Full-text]
30. Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.
    Gynecol Oncol, 103(2): 570-4. [Abstract] [Full-text]
31. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
    Gynecol Oncol, 103(2): 512-7. [Abstract] [Full-text]
32. Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases.
    Gynecol Oncol, 103(2): 565-9. [Abstract] [Full-text]
33. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Gynecol Oncol, 103(2): 405-16. [Abstract] [Full-text]
34. Outcomes for systemic therapy in women with ovarian cancer.
    Gynecol Oncol, 103(2): 554-8. [Abstract] [Full-text]
35. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Gynecol Oncol, 103(2): 559-64. [Abstract] [Full-text]
36. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.
    Gynecol Oncol, 103(2): 719-28. [Abstract] [Full-text]
37. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
    Gynecol Oncol, 103(2): 483-8. [Abstract] [Full-text]
38. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
    Gynecol Oncol, 103(2): 446-50. [Abstract] [Full-text]
39. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
    Gynecol Oncol, 103(2): 439-45. [Abstract] [Full-text]
40. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
    Gynecol Oncol, 103(2): 473-8. [Abstract] [Full-text]
41. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 103(2): 391-6. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.